TITLE

Success of Vaccine Offers Promise of Cervical Cancer Prevention

AUTHOR(S)
Schultz, James
PUB. DATE
January 2003
SOURCE
JNCI: Journal of the National Cancer Institute;1/15/2003, Vol. 95 Issue 2, p103
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Cites the key findings of Merck and Company Inc.'s clinical trials on an investigational vaccine against the human papillomavirus type 16. Key issues of interest; Analysis of pertinent topics and relevant issues; Implications on cervical cancer prevention.
ACCESSION #
9033251

 

Related Articles

  • Merck HIV Vaccine Ineffective in Clinical Trial.  // Travel Medicine Advisor;Nov2007, Vol. 17 Issue 11, p2 

    The article reports on the ineffectiveness of HIV vaccine from Merck in a large clinical trial that made the company halt further test vaccinations. A trial which was started in 2004 has identified 24 new HIV infections in the group who received the vaccine compared to 21 infections in the...

  • EDITORIAL. Stevceva, Liljana // Current Medicinal Chemistry;Sep2011, Vol. 18 Issue 26, p3952 

    No abstract available.

  • Two HPV Vaccines Yielding Similar Success. Washam, Cynthia // JNCI: Journal of the National Cancer Institute;7/20/2005, Vol. 97 Issue 14, p1030 

    Reports on the final phase of the clinical trials of Merck & Co. and GlaxoSmithKline PLC's vaccines against human papillomavirus (HPV) types 16 and 18. Immunity against HPV 6 and 11 provided by Merck's Gardasil; Results of earlier trials of Gardasil and GlaxoSmithKline's Cervarix vaccines;...

  • HIV vaccine failure prompts Merck to halt trial.  // Nature;9/27/2007, Vol. 449 Issue 7161, p390 

    The article reports on the failure of the human immunodeficiency virus (HIV) vaccine developed by Merck in the U.S. It is stated that the failure has caused Merck to halt its clinical trials. It reveals that the latest trial had begun in 2004 which enrolled 3,000 people considered to be at high...

  • HPV vaccine benefit extends past current age indication. Huh, Warner; Shafer, Emily // Hem/Onc Today;4/10/2008, Vol. 9 Issue 6, p26 

    The article discusses the data from FUTURE III, a phase-3 trial of the quadrivalent human papillomavirus vaccine, Gardasil from Merck. The data was presented by Sharmila Makhija, an associate professor in the division of gynecologic oncology of the University of Alabama at Birmingham. The women...

  • Pharma: Clinic Roundup.  // BioWorld Today;4/3/2012, Vol. 23 Issue 64, p8 

    This section offers news briefs on clinical trials in the pharmaceutical sector. Positive results were obtained by Merck & Co. Inc. from a Phase III trial of its shingles vaccine Zosvatax. Novartis AG claims that its QVA149 has met the primary endpoints of trials in patients with chronic...

  • Separate measles, mumps, rubella vaccine formulations discontinued. Blazek, Nicole; Zacharyczuk, Colleen // Infectious Disease News;Nov2009, Vol. 22 Issue 11, p35 

    This article reveals the plan of Merck to discontinue production of monovalent measles, mumps, rubella vaccine formulations.

  • HIV: The next shot. Hayden, Erica Check // Nature;7/31/2008, Vol. 454 Issue 7204, p565 

    The article provides information on the role of HIV Vaccine Trials Network head Larry Corey and HIV researcher Colleen Doyle in developing a vaccine for HIV. Information on Corey's success as a scientist as well as the childhood life of Doyle and how her passion for science continued after her...

  • PROTECTIVE POTATO.  // Science Teacher;Oct2000, Vol. 67 Issue 7, p18 

    Reports on the clinical trials for Norwalk virus plant-based vaccine in the United States. Estimates on the prevalence of Norwalk vaccine infection in the country; Stages of the trials.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics